Thyroid eye disease (TED) therapy Tepezza – the very best asset in Amgen's $26 billion takeover of Horizon in 2023 – can be struggling with Level of competition from A neater-to-dose alternative from Sling Therapeutics. Zeidan was Beforehand the Main growth officer at Millend